novo nordisk ozempic - Search News

News

Novo Nordisk to sell Ozempic

Fortune on MSN · 4h

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

Novo Nordisk has announced a sweeping reduction in the cost of its blockbuster diabetes drug Ozempic, cutting the monthly price for cash-paying U.S. patients with type 2 diabetes from its previous list price of nearly $1,

Fox Business on MSN · 4h

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

CNN on MSN · 21m

US patients can now get Ozempic for half price if they can pay cash

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don’t go through insurance.

5hon MSN

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to ...

6hon MSN

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

5h

Stock Movers: Novo Nordisk, GoodRX, CVS

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

3m

Should You Buy the Pop in Novo Nordisk Stock?

Novo Nordisk stock rallies as the Danish pharma giant makes two big announcements. TD Cowen analysts recommend buying NVO ...

25m

Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

The Pharma Letter2d

MASH win for Novo Nordisk’s Wegovy

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1drug Wegovy (semaglutide), as the US Food and Drug ...

Zacks.com on MSN3d

Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results